Jeffrey Lancet

19PUBLICATIONS
88CO-AUTHORS
Haematological tumoursMedical molecular engineering of nucleic acids and proteinsCancer therapy (excl. chemotherapy and radiation therapy)Gene and molecular therapyImmunogenetics (incl. genetic immunology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (19)

|May 06, 2026
Cardiovascular Adverse Events During Venetoclax-Based Treatment in Acute Myeloid Leukemia.

|Feb 11, 2026
Prognostic Model Combining Mutational and Cytogenetic Profiles in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents.

Dimitrios Drekolias, Fatima Tuz Zahra, Caroline Fileni

|Aug 07, 2025
Hypomethylating Agent and Venetoclax Combination Is a Safe and Effective Alternative to Intensive Chemotherapy in Older (≥ 70 Years) Patients With Newly Diagnosed Favorable Risk Acute Myeloid Leukemia.

Somedeb Ball, Akriti G Jain, Najla Al Ali

|Jun 20, 2024
Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatment.

Sylvain Garciaz, Pierre-Yves Dumas, Sarah Bertoli

|Sep 14, 2023
Drivers of deep molecular response and long-term outcomes in patients with core binding factor acute myeloid leukemia.

Parth C Patel, Somedeb Ball, Akriti G Jain

|Jun 28, 2023
Safety and immunogenicity of a third dose of mRNA-1273 vaccine among cancer patients.

Anna Giuliano, Barbara Kuter, Shari Pilon-Thomas

Pageof 4

Frequent Collaborators

14 joint publications

Rami S Komrokji

14 joint publications

David Sallman

9 joint publications

Onyee Chan

7 joint publications

Eric Padron